• Lantern Pharma published Phase 1a results for LP-184 in recurrent glioblastoma in the October 2026 issue of Cancer Research Communications.
• Treatment was generally well tolerated, but no objective tumor responses were observed; limited brain exposure constrained its potential as a standalone therapy.
• Preclinical findings support combining LP-184 with spironolactone to increase tumor sensitivity rather than raising the dose.
• Subsidiary Starlight Therapeutics will sponsor a planned Phase 1b/2a combination trial in patients with glioblastoma at first recurrence following standard therapy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lantern Pharma Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261110780032) on November 10, 2026, and is solely responsible for the information contained therein.